Basic Information
RNALocate ID: | RLID:11001789 |
RNA Symbol: | hsa-miR-142-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-142-3p |
RNA ID: | miRBase:MIMAT0000434 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 22427800 |
Tissue/Cell Line: | Serum |
Method: | qRT-PCR |
Description: | The miRNAs tested in serum and saliva samples are shown in Table 1. These miRNAs were selected because they are either ubiquitously expressed or have been reported as biomarkers (Table 1). The relative concentration of these microRNAs was determined by calculating the difference of Ct values between the exosome samples and the exosome-depleted supernatant. A 1-unit difference in the Ct value between the miRNAs isolated from the exosomal pellet or supernatant represents a 2-fold difference in the amount of input miRNA. Data are collected from Table 1: List of miRNAs tested in serum and saliva samples. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001786 | Endoplasmic reticulum membrane | Cortical tissue | 32451872 |
RLID:11001787 | Exosome | B cell line (Raji)|Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001788 | Exosome | Breast milk | 22211110 |
RLID:11001790 | Exosome | Brain tissue | 23382797 |
RLID:11001791 | Exosome | Plasma | 23663360 |
RLID:11001792 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001794 | Microvesicle | Plasma | 19951903 |
RLID:11001795 | Microvesicle | Liver resident stem cells | 20668554 |
RLID:11001796 | Microvesicle | Hepatoma cells | 23771658 |
RLID-D:11000084 | Exosome | B lymphoblastoid cells|Chronic lymphocytic leukemia cells|Lymphoma tissue|Mast cells | |
RLID-D:11000362 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-142-3p | Mantle cell lymphoma | MNDR-E-MI-13915 |
MNDR | hsa-miR-142-3p | Splenic marginal zone lymphoma | MNDR-E-MI-13916 |
MNDR | hsa-miR-142-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-13917 |
MNDR | hsa-miR-142-3p | Oral squamous cell carcinoma | MNDR-E-MI-13918 |
MNDR | hsa-miR-142-3p | Medulloblastoma | MNDR-E-MI-13919 |
MNDR | hsa-miR-142-3p | B cell lymphoma of malt type | MNDR-E-MI-13920 |
MNDR | hsa-miR-142-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-13921 |
MNDR | hsa-miR-142-3p | Lymphoma | MNDR-E-MI-13922 |
MNDR | hsa-miR-142-3p | Lymphoma non-hodgkin | MNDR-E-MI-13923 |
MNDR | hsa-miR-142-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-13924 |
MNDR | hsa-miR-142-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-13925 |
MNDR | hsa-miR-142-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-13926 |
MNDR | hsa-miR-142-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-13927 |
MNDR | hsa-miR-142-3p | Her2-receptor positive breast cancer | MNDR-E-MI-13928 |
MNDR | hsa-miR-142-3p | Breast cancer luminal | MNDR-E-MI-13929 |
MNDR | hsa-miR-142-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-13930 |
MNDR | hsa-miR-142-3p | Dermatomyositis | MNDR-E-MI-13931 |
MNDR | hsa-miR-142-3p | Prostate cancer | MNDR-E-MI-13932 |
MNDR | hsa-miR-142-3p | Hirschsprung disease | MNDR-E-MI-13933 |
MNDR | hsa-miR-142-3p | Gastric cancer | MNDR-E-MI-13934 |
MNDR | hsa-miR-142-3p | Pre-eclampsia | MNDR-E-MI-13935 |
MNDR | hsa-miR-142-3p | Alzheimer disease | MNDR-E-MI-13936 |
MNDR | hsa-miR-142-3p | Sarcoma | MNDR-E-MI-13937 |
MNDR | hsa-miR-142-3p | Dysautonomia familial | MNDR-E-MI-13938 |
MNDR | hsa-miR-142-3p | Leukemia | MNDR-E-MI-13939 |
MNDR | hsa-miR-142-3p | Huntington disease | MNDR-E-MI-13940 |
MNDR | hsa-miR-142-3p | Chorea | MNDR-E-MI-13941 |
MNDR | hsa-miR-142-3p | Cardiovascular disease | MNDR-E-MI-13942 |
MNDR | hsa-miR-142-3p | Moyamoya disease | MNDR-E-MI-13943 |
MNDR | hsa-miR-142-3p | Lung cancer | MNDR-E-MI-13944 |
MNDR | hsa-miR-142-3p | Down syndrome | MNDR-E-MI-13945 |
MNDR | hsa-miR-142-3p | Parkinson disease | MNDR-E-MI-13946 |
MNDR | hsa-miR-142-3p | Basal-like breast cancer | MNDR-E-MI-13947 |
MNDR | hsa-miR-142-3p | Thyroid cancer | MNDR-E-MI-13948 |
MNDR | hsa-miR-142-3p | Pituitary neoplasms | MNDR-E-MI-13949 |
MNDR | hsa-miR-142-3p | Pancreatic cancer | MNDR-E-MI-13950 |
MNDR | hsa-miR-142-3p | Melanoma | MNDR-E-MI-13951 |
MNDR | hsa-miR-142-3p | Rectum adenocarcinoma | MNDR-E-MI-13952 |
MNDR | hsa-miR-142-3p | Colon cancer | MNDR-E-MI-13953 |
MNDR | hsa-miR-142-3p | Ischemic attack transient | MNDR-E-MI-13954 |
MNDR | hsa-miR-142-3p | Colon adenocarcinoma | MNDR-E-MI-13955 |
MNDR | hsa-miR-142-3p | Multiple sclerosis | MNDR-E-MI-13956 |
MNDR | hsa-miR-142-3p | Relapsing-remitting multiple sclerosis | MNDR-E-MI-13957 |
MNDR | hsa-miR-142-3p | Familial ovarian cancer | MNDR-E-MI-13958 |
MNDR | hsa-miR-142-3p | Asthma | MNDR-E-MI-13959 |
MNDR | hsa-miR-142-3p | Endometriosis | MNDR-E-MI-13960 |
MNDR | hsa-miR-142-3p | Carcinoma ductal breast | MNDR-E-MI-13961 |
MNDR | hsa-miR-142-3p | Glioblastoma | MNDR-E-MI-13962 |
MNDR | hsa-miR-142-3p | Astrocytoma | MNDR-E-MI-13963 |
MNDR | hsa-miR-142-3p | Malignant glioma | MNDR-E-MI-13964 |
MNDR | hsa-miR-142-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-13965 |
MNDR | hsa-miR-142-3p | Osteosarcoma | MNDR-E-MI-13966 |
MNDR | hsa-miR-142-3p | Liposarcoma | MNDR-E-MI-13967 |
MNDR | hsa-miR-142-3p | Breast carcinoma | MNDR-E-MI-13968 |
MNDR | hsa-miR-142-3p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-13969 |
MNDR | hsa-miR-142-3p | Meningioma | MNDR-E-MI-13970 |
MNDR | hsa-miR-142-3p | Uterine cancer | MNDR-E-MI-13971 |
MNDR | hsa-miR-142-3p | Gastric adenocarcinoma | MNDR-E-MI-13972 |
MNDR | hsa-miR-142-3p | Cervical squamous cell carcinoma | MNDR-E-MI-13973 |
MNDR | hsa-miR-142-3p | Pituitary adenoma | MNDR-E-MI-13974 |
MNDR | hsa-miR-142-3p | Lung squamous cell carcinoma | MNDR-E-MI-13975 |
MNDR | hsa-miR-142-3p | Carcinoma lung non-small-cell | MNDR-E-MI-13976 |
MNDR | hsa-miR-142-3p | Lung adenocarcinoma | MNDR-E-MI-13977 |
MNDR | hsa-miR-142-3p | Thyroid carcinoma | MNDR-E-MI-13978 |
MNDR | hsa-miR-142-3p | Bladder urothelial carcinoma | MNDR-E-MI-13979 |
MNDR | hsa-miR-142-3p | Pancreatic adenocarcinoma | MNDR-E-MI-13980 |
MNDR | hsa-miR-142-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-13981 |
MNDR | hsa-miR-142-3p | Carcinoma renal cell | MNDR-E-MI-13982 |
MNDR | hsa-miR-142-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-13983 |
MNDR | hsa-miR-142-3p | Clear cell renal cell carcinoma | MNDR-E-MI-13984 |
MNDR | hsa-miR-142-3p | Cholangiocarcinoma | MNDR-E-MI-13985 |
MNDR | hsa-miR-142-3p | Prolactinoma | MNDR-E-MI-13986 |
MNDR | hsa-miR-142-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-13987 |
MNDR | hsa-miR-142-3p | Testicular germ cell cancer | MNDR-E-MI-13988 |
MNDR | hsa-miR-142-3p | Kidney diseases | MNDR-E-MI-13989 |
MNDR | hsa-miR-142-3p | T-cell acute lymphoblastic leukemia | MNDR-E-MI-13990 |
MNDR | hsa-miR-142-3p | Fibromyalgia | MNDR-E-MI-13991 |
MNDR | hsa-miR-142-3p | Breast invasive carcinoma | MNDR-E-MI-13992 |
MNDR | hsa-miR-142-3p | Hepatocellular carcinoma | MNDR-E-MI-13993 |
MNDR | hsa-miR-142-3p | Embryonal cancer | MNDR-E-MI-13994 |
MNDR | hsa-miR-142-3p | Familiar ovarian carcinoma | MNDR-E-MI-13995 |
MNDR | hsa-miR-142-3p | B-cell lymphoma | MNDR-E-MI-13996 |
MNDR | hsa-miR-142-3p | Rheumatoid arthritis | MNDR-E-MI-13997 |
MNDR | hsa-miR-142-3p | Osteoarthritis | MNDR-E-MI-13998 |
MNDR | hsa-miR-142-3p | Hodgkin lymphoma | MNDR-E-MI-13999 |
MNDR | hsa-miR-142-3p | Ulcerative colitis | MNDR-E-MI-14000 |
MNDR | hsa-miR-142-3p | Burkitt lymphoma | MNDR-E-MI-14001 |
MNDR | hsa-miR-142-3p | Tonsil cancer | MNDR-E-MI-14002 |
MNDR | hsa-miR-142-3p | Neuromyelitis optica | MNDR-E-MI-14003 |
MNDR | hsa-miR-142-3p | Psoriasis | MNDR-E-MI-14004 |
MNDR | hsa-miR-142-3p | Skin cutaneous melanoma | MNDR-E-MI-14005 |
MNDR | hsa-miR-142-3p | Skin melanoma | MNDR-E-MI-14006 |
MNDR | hsa-miR-142-3p | Acute myeloid leukemia | MNDR-E-MI-14007 |
MNDR | hsa-miR-142-3p | Colorectal cancer | MNDR-E-MI-14008 |
MNDR | hsa-miR-142-3p | Nasopharyngeal carcinoma | MNDR-E-MI-14009 |
MNDR | hsa-miR-142-3p | Nasopharynx carcinoma | MNDR-E-MI-14010 |
MNDR | hsa-miR-142-3p | Multiple myeloma | MNDR-E-MI-14011 |
MNDR | hsa-miR-142-3p | Acute lymphoblastic leukemia | MNDR-E-MI-14012 |
MNDR | hsa-miR-142-3p | Ependymoma | MNDR-E-MI-14013 |
MNDR | hsa-miR-142-3p | Nasopharyngeal cancer | MNDR-E-MI-14014 |
MNDR | hsa-miR-142-3p | Prostatic neoplasms | MNDR-E-MI-14015 |
MNDR | hsa-miR-142-3p | Aids dementia complex | MNDR-E-MI-14016 |
MNDR | hsa-miR-142-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-14017 |
MNDR | hsa-miR-142-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-14018 |
MNDR | hsa-miR-142-3p | Stroke lacunar | MNDR-E-MI-14019 |
MNDR | hsa-miR-142-3p | Breast cancer her3+ negative | MNDR-E-MI-14020 |
MNDR | hsa-miR-142-3p | Multiple sclerosis susceptibility | MNDR-E-MI-14021 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCG2 | Homo sapiens | RR00024737 |
TOP